Updated Jul 16, 2026 · Last SEC filing 2026-07-09
Vera Therapeutics, Inc. (VERA) has filed 11 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-09. 5 Form 8-K material event filings were reported by VERA in the last 90 days. 2 Form 144 notices of proposed sale were filed for VERA stock. InsiderAlpha tracks every VERA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001831828 |
|---|
| Form 4 filings (90d) | 11 |
|---|---|
| Form 8-K filings (90d) | 5 |
| Form 144 notices (90d) | 2 |
| Latest Form 4 filing | 2026-07-09 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 32.5K | $42.07 | $1.37M | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 2.2K | $43.59 | $96K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 1.0K | $40.78 | $41K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 10.5K | $42.86 | $450K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 88 | $38.43 | $3K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 18.4K | $37.93 | $698K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 4.3K | $37.09 | $159K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 14.2K | $36.64 | $521K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 900 | $45.51 | $41K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 7.9K | $44.58 | $353K | SEC | |
| Fordyce Marshall | PRESIDENT AND CEO | S — Open-market sale | 14.1K | $43.66 | $617K | SEC | |
| Wright-Mitchell Jane | Chief Legal Officer | A — Grant or award | 42.4K | $0.00 | — | SEC | |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | M — Option exercise | 10.0K | $3.94 | $39K | SEC | |
| Skelton Laurence Matthew | Chief Commercial Officer | S — Open-market sale | 1.6K | $41.98 | $66K | SEC | |
| JOHNSON DAVID LEE | Chief Operating Officer | S — Open-market sale | 2.6K | $41.98 | $108K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Vera Therapeutics, Inc. (VERA). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Fordyce Marshall | 8 | $3.34M |
| Cheng Andrew | 1 | — |
| Morrison Scott W | 1 | — |
| Meyers James R | 1 | — |
| SEIDENBERG BETH C | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in VERA insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live VERA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.